In Brief: Exogen
This article was originally published in The Gray Sheet
Exogen: Health Care Financing Administration denies Medicare reimbursement coverage for the firm's Sonic Accelerated Fracture Healing System, Exogen announces Aug. 23. The Piscataway, New Jersey firm says it is "disappointed" in HCFA's determination and plans "to aggressively pursue all avenues to reverse this decision." Exogen says it presented HCFA with "clinical and economic outcome data" on 105 Medicare patients treated with the system and reported a 94% healing rate, adding that it "estimates that a significant economic benefit well above the cost of the SAFHS therapy has been realized by these patients." The firm also reports that it has not recorded any revenues from Medicare sales...
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.